Article info
PDFNeurodegeneration
Review
Clinical utility of cerebrospinal fluid biomarkers in the evaluation of cognitive impairment: a systematic review and meta-analysis
- Correspondence to Dr Jemma Hazan, University College London, London, UK; j.hazan{at}ucl.ac.uk
Citation
Clinical utility of cerebrospinal fluid biomarkers in the evaluation of cognitive impairment: a systematic review and meta-analysis
Publication history
- Received May 4, 2022
- Accepted August 29, 2022
- First published September 12, 2022.
Online issue publication
January 11, 2023
Article Versions
- Previous version (11 January 2023).
- You are viewing the most recent version of this article.
Supplementary Data
This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© Author(s) (or their employer(s)) 2023. No commercial re-use. See rights and permissions. Published by BMJ.